Influence of compliance on the incidence of cardiovascular events and health costs when using single-pill fixed-dose combinations for the treatment of hypertension

Published: November 23, 2010
Category: Bibliography > Papers
Authors: Galera Llorca J, Munoz Orti G, Navarro-Artieda R, Sicras-Mainar A
Countries: Spain
Language: null
Types: Care Management
Settings: Hospital

Med Clin (Barc) 136:183-191.

Directorate of Planning, Badalona Serveis Assistencials SA, Badalona, Spain

BACKGROUND AND OBJECTIVE: To determine the incidence of cardiovascular events (CVE) and health care costs in relation to compliance, persistence and level of blood pressure control when comparing patients treated with single-pill combinations (SPC) or free combinations (FC) for the treatment of hypertension.

PATIENTS AND METHODS: Observational, multicenter study that included patients > 30 years old, from six primary care teams and two hospitals, who started pharmacological treatment for hypertension during 2006. Two study groups were established: SPC (ACEIs/diuretics; ARBs/diuretics) and FC (ACEIs + DIU; ARB + DIU, separately). Main variables studied were sociodemographic data, comorbidity, Charlson-index, compliance, persistence and achievement of therapeutic goals (ESH-ESC criteria). The cumulative incidence of CVE and a total-cost model were determined (differentiating: health/direct; non-health/indirect). Patients were followed for two years. Statistical analysis included logistic regression, Cox proportional hazards model and analysis of covariance. Statistical signification: p < 0.05.

RESULTS: 1,605 patients were recruited, 1,112 (69.3%) receiving SPC and 493 (30.7%) receiving FC, p 0.001; mean age: 69.4 (12.2) years; women: 55.5%. FC treatments were associated with ischaemic heat disease (OR = 1.4; 95% CI: 1.1-2.0) and organ failure (OR = 1.5; 95% CI: 1.2-2.1), p 0.031. Patients on SPC showed better therapeutic compliance (77.6% vs 71.9%; p 0.001) and longer persistence of treatment (62.1% on-treatment at 24-months [9% CI: 56.3-67.9] vs 49.7 [95% CI: 38.5-60.9]; p 0.001). Optimal control of blood pressure was higher in SPC (48.9% [95% CI: 43.0-54.8] vs 46.7% [95% CI: 35.6-57.8]; p 0.00). Cumulative incidence of cerebrovascular accidents in FC was 4.6% vs 2.4% in SPC; p = 0.041. The total health cae costs were lower in SPC (1,650.7 € vs 1,674.8 €; p 0.001), including lower specialized care costs (316.1 € vs 382.9 €; p 0.001), fewer hospital admissions and less loss of labour productivity (4.5 € vs 88.4 €; p < .001).

CONCLUSIONS: Better compliance and persistence with antihypertensive fixed-dose combinations improves therapeutic control, leading to a significant reduction of cerebrovascular accidents and total health care costs.

Medication,Cost Burden Evaluation,Medical Conditions,Spain,Absenteeism,Adult,Aged,80 and over,Anthropometry,Antihypertensive Agents/administration & dosage,Antihypertensive Agents/classification,Cardiovascular Diseases/economics,Cardiovascular Diseases/etiology,Cardiovascular Diseases/prevention & control,Co-morbidity,Drug Combinations,Gender,Follow-Up Studies,Hospitalization/economics,Hospitals,Special/statistics & numerical data,Hospitals,Urban/statistics & numerical data,Hypertension/blood,Hypertension/complications,Hypertension/physiopathology,Incidence,Middle Aged,Primary Health Care,Risk Assessment,Socioeconomic Factors,Spain/epidemiology,Stroke/economics,Stroke/epidemiology,Stroke/etiology,Stoke/prevention & control,Tablets

Please log in/register to access.

Log in/Register

LinkedIn Facebook Twitter

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System.
All rights reserved. Terms of Use Privacy Statement

Back to top